Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib + Regorafenib in Metastatic Colorectal Cancer
NCT02119676Phase 2Terminated
- Sponsor
- Incyte
- Start
- Mar 2014
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of ruxolitinib in colorectal cancer (metastatic) (mCRC), sponsored by Incyte. Started Mar 2014; status: terminated.
02
Drugs
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT02119676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02119676.